2 Information about nusinersen

Information about nusinersen

Marketing authorisation indication

Nusinersen (Spinraza, Biogen Idec) has a marketing authorisation for 'the treatment of 5q spinal muscular atrophy'.

Dosage in the marketing authorisation

12 mg, by intrathecal infusion, on days 0, 14, 28 and 63, then every 4 months.


The list price is £75,000 per vial (excluding VAT; BNF, accessed June 2018).

At the list price, the total annual treatment cost is £450,000 for the first year and £225,000 for subsequent years. Over 5 years, the treatment costs per person would be £1.35 million.

The company has a commercial arrangement. This makes nusinersen available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)